| Identification | Back Directory | [Name]
AQW-051 | [CAS]
669770-29-0 | [Synonyms]
AQW-051
669770-29-0
AQW-051
(AQW051
(R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine
1-Azabicyclo[2.2.2]octane, 3-[[6-(4-methylphenyl)-3-pyridinyl]oxy]-, (3R)- | [Molecular Formula]
C19H22N2O | [MDL Number]
MFCD28502153 | [MOL File]
669770-29-0.mol | [Molecular Weight]
294.39 |
| Chemical Properties | Back Directory | [Boiling point ]
443.8±45.0 °C(Predicted) | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Store at 0-8 °C | [solubility ]
Ethanol: Soluble: =10 mg/ml | [form ]
Solid | [pka]
9.09±0.33(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety[1]. | [in vivo]
VQW-765 (0.03 and 0.3 mg/kg; oral administration once) increases cognitive effect and learning/memory performance in mice[1].
VQW-765 (1 mg/kg; oral administration once) shows anxiolytic-like effect with increasing the social exploration time in rats with a duration of at least 6 h[1]. | Animal Model: | OF1/IC strain adult mice[1] | | Dosage: | 0.03 and 0.3 mg/kg | | Administration: | Oral administration; 0.03 and 0.3 mg/kg once | | Result: | Increased the learning/memory performance with more time to scrutinize the novel partner than the familiar partner during the re-test trial at 24 h. Showed cognitive-enhancing effects in mice by the object recognition test (ORT).
|
| [References]
[1] Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304. DOI:10.1111/bph.13001 |
|
| Company Name: |
Elucigen bio
|
| Tel: |
13501719342; 13501719342 |
| Website: |
|
|